A Century of Innovation Now Focused on Transplantation
For over 100 years, CSL Behring has put patients first by delivering on its promise to discover and develop innovative life-changing therapies to address many of the world’s most serious and rare disorders. We’re now bringing that same commitment to transplantation.
Committed to Our Mission
CSL Behring recognizes that the transplant community continues to face significant challenges in both solid organ and stem cell transplantation. We look to apply our leadership, experience, and discoveries in immunology and autoimmune diseases to help patients who require, or have received, a transplant.
Solid Organ Transplant
While advances in solid organ transplantation techniques and therapies have markedly improved allograft survival, organ rejection remains one of the greatest limitations in transplantation. According to the Organ Procurement and Transplantation Network (OPTN), over 109,000 people in the United States alone are currently on the waiting list for a lifesaving organ transplant, making it critically important to extend the survival of this extraordinary gift of life.
Antibody-mediated rejection (AMR) is a significant complication that leads to organ dysfunction and loss, and there is significant unmet need for effective treatments.
Our immediate mission is to offer new hope to kidney transplant recipients by investigating new therapies to address AMR and improve patient outcomes.
Stem Cell Transplant
Stem cell transplantation, also known as hematopoietic cell transplant (HCT) or bone marrow transplant, is a potentially curative treatment for certain blood cancers with proper donor/recipient matches. According to the Center for International Blood & Marrow Transplant Research (CIBMTR), approximately 27,000 allogeneic cell transplants (donor cells) were performed in the United States and Europe in 2017. Acute graft-versus-Host Disease (GvHD) is a life-threatening immunological complication of allogeneic HCT and a leading cause of mortality and morbidity after transplant. There is a significant unmet need for more effective, less toxic therapies for prevention and treatment of GvHD.
Through a commitment to ongoing research, CSL Behring is dedicated to investigating new therapies for patients to prevent and treat GvHD following allogeneic hematopoietic cell transplant.
" At CSL, we work each day as if someone’s life depends on it - because it really does. "Paul Perrault
CEO and Managing Director, CSL Behring